CL2007001614A1 - Polipeptido que comprende una proteina del precursor del factor de crecimiento tipo insulina, igf-1 humana, en la cual la escision del peptido e mediante una proteasa se reduce a traves de la modificacion de la proteina del precursor; y su uso para t - Google Patents

Polipeptido que comprende una proteina del precursor del factor de crecimiento tipo insulina, igf-1 humana, en la cual la escision del peptido e mediante una proteasa se reduce a traves de la modificacion de la proteina del precursor; y su uso para t

Info

Publication number: CL2007001614A1
Authority: CL; Chile
Prior art keywords: protein; igf; protease; polypeptide; peptide
Prior art date: 2006-06-09

Application number

CL200701614A

Other languages

English (en)

Inventor

David Jonathan Y Fornaro Glass

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-06-09

Filing date

2007-06-06

Publication date

2008-08-08

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38801859&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2007001614(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-06-06 Application filed by Novartis Ag filed Critical Novartis Ag

2008-08-08 Publication of CL2007001614A1 publication Critical patent/CL2007001614A1/es

Links

NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title 2
108090000765 processed proteins & peptides Proteins 0.000 title 2
102000004169 proteins and genes Human genes 0.000 title 2
108090000623 proteins and genes Proteins 0.000 title 2
102000004877 Insulin Human genes 0.000 title 1
108090001061 Insulin Proteins 0.000 title 1
108090000723 Insulin-Like Growth Factor I Proteins 0.000 title 1
102000004218 Insulin-Like Growth Factor I Human genes 0.000 title 1
108091005804 Peptidases Proteins 0.000 title 1
239000004365 Protease Substances 0.000 title 1
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 title 1
239000003102 growth factor Substances 0.000 title 1
229940125396 insulin Drugs 0.000 title 1
230000004048 modification Effects 0.000 title 1
238000012986 modification Methods 0.000 title 1
229920001184 polypeptide Polymers 0.000 title 1
239000002243 precursor Substances 0.000 title 1
102000004196 processed proteins & peptides Human genes 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Zoology (AREA)
Physical Education & Sports Medicine (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Toxicology (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurology (AREA)
Immunology (AREA)
Neurosurgery (AREA)
Rheumatology (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Hospice & Palliative Care (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Pulmonology (AREA)
Psychiatry (AREA)
Ophthalmology & Optometry (AREA)

CL200701614A 2006-06-09 2007-06-06 Polipeptido que comprende una proteina del precursor del factor de crecimiento tipo insulina, igf-1 humana, en la cual la escision del peptido e mediante una proteasa se reduce a traves de la modificacion de la proteina del precursor; y su uso para t CL2007001614A1 (es)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date
US81234906P	2006-06-09	2006-06-09
US86224406P	2006-10-20	2006-10-20
US89718707P	2007-01-24	2007-01-24

Publications (1)

Publication Number	Publication Date
CL2007001614A1 true CL2007001614A1 (es)	2008-08-08

Family

ID=38801859

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL200701614A CL2007001614A1 (es)	2006-06-09	2007-06-06	Polipeptido que comprende una proteina del precursor del factor de crecimiento tipo insulina, igf-1 humana, en la cual la escision del peptido e mediante una proteasa se reduce a traves de la modificacion de la proteina del precursor; y su uso para t

Country Status (32)

Country	Link
US (4)	US8343918B2 (es)
EP (2)	EP2032155B1 (es)
JP (2)	JP2009539805A (es)
KR (1)	KR101459789B1 (es)
AR (1)	AR061242A1 (es)
AU (2)	AU2007257936B2 (es)
BR (2)	BRPI0712147A2 (es)
CA (2)	CA2653781A1 (es)
CL (1)	CL2007001614A1 (es)
CR (2)	CR10432A (es)
CY (1)	CY1116117T1 (es)
DK (2)	DK2032155T3 (es)
EC (1)	ECSP088949A (es)
ES (1)	ES2529261T3 (es)
GT (1)	GT200800273A (es)
HR (1)	HRP20150326T1 (es)
IL (1)	IL195156A (es)
JO (1)	JO2968B1 (es)
MA (1)	MA30503B1 (es)
MX (2)	MX2008015726A (es)
MY (1)	MY147856A (es)
NO (2)	NO20085183L (es)
NZ (2)	NZ572708A (es)
PE (1)	PE20080715A1 (es)
PL (1)	PL2032155T3 (es)
PT (1)	PT2032155E (es)
RU (1)	RU2477287C2 (es)
SI (1)	SI2032155T1 (es)
TN (1)	TNSN08509A1 (es)
TW (1)	TWI427084B (es)
UA (1)	UA97953C2 (es)
WO (2)	WO2007141309A2 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20090318355A1 (en) *	2006-02-15	2009-12-24	Chen Thomas T	Compositions and methods for promoting tissue repair and wound healing
UA97953C2 (uk) *	2006-06-09	2012-04-10	Новартіс Аг	Стабілізовані поліпептиди інсуліноподібного фактора росту
BR122017015900A2 (pt) *	2008-05-07	2019-09-10	Biomarin Pharm Inc	ácido nucleico e células
BRPI0921261A2 (pt) *	2008-11-10	2018-10-23	Novartis Ag	anticorpos que se ligam imunoespecificamente a peptídeos igf-1 humanos modificados , hibridoma, polipeptídeo isolado, ácido nucleico que codifica um anticorpo, vetor compreendendo um ácido nucléico, célula hospedeira compreendendo um vetor, ensaio imunosorvente ligado a enzima aperfeiçoado (elisa), método de manter uma dose ótima de igf-1/e modificada, método cromatográfico de afinidade aperfeiçoado e uso de igf-1/e modificado.
US8685403B2 (en) *	2009-01-30	2014-04-01	The Regents Of The University Of California	Insulin-like growth factor signaling and integrin
MY153078A (en)	2009-04-27	2014-12-31	Novartis Ag	Compositions and methods for increasing muscle growth
AU2010275010B2 (en) *	2009-07-22	2013-10-24	Ipsen Pharma S.A.S.	Analogues of insulin-like growth factor-1 (IGF-1) having amino acid substitution at position 59
WO2011057249A2 (en) *	2009-11-09	2011-05-12	The Brigham And Women's Hospital, Inc.	Treatment of heart disease
JP2011160696A (ja) *	2010-02-08	2011-08-25	Novartis Ag	修飾ヒトｉｇｆ−１／ｅペプチドに対する抗体
EP2709647B1 (en)	2011-02-23	2019-08-07	Massachusetts Institute Of Technology	Water soluble membrane proteins and methods for the preparation and use thereof
US20140357558A1 (en) *	2011-06-24	2014-12-04	Cold Spring Harbor Laboratory	Compositions and methods for treatment of spinal muscular atrophy
WO2013006437A1 (en)	2011-07-01	2013-01-10	Novartis Ag	Method for treating metabolic disorders
WO2014012025A2 (en)	2012-07-13	2014-01-16	The Trustees Of The University Of Pennsylvania	Igf-1 proteins and therapeutic uses thereof
EA034356B1 (ru) *	2012-12-18	2020-01-30	Новартис Аг	Вариантный белок igf-1 человека и содержащая его композиция для лечения мышечного расстройства
CN104884467A (zh) *	2012-12-18	2015-09-02	诺华股份有限公司	在遗传修饰的哺乳动物细胞中生产治疗性蛋白质
TW201536318A (zh)	2013-08-14	2015-10-01	Novartis Ag	治療偶發性包涵體肌炎之方法
CA2926173A1 (en)	2013-10-02	2015-04-09	Novartis Ag	Insulin-like growth factor mimetics for use in therapy
UY35874A (es)	2013-12-12	2015-07-31	Novartis Ag	Un proceso para la preparación de una composición de proteínas pegiladas
KR102313381B1 (ko) *	2013-12-19	2021-10-14	퓨어테인 바이오사이언스, 엘엘씨.	동물을 치료하기 위한 방법
CN105992951A (zh)	2014-01-27	2016-10-05	诺华股份有限公司	预测肌萎缩的生物标志物、方法和用途
US10373702B2 (en)	2014-03-27	2019-08-06	Massachusetts Institute Of Technology	Water-soluble trans-membrane proteins and methods for the preparation and use thereof
WO2015149085A2 (en) *	2014-03-27	2015-10-01	Massachusetts Institute Of Technology	Warer-soluble trans-membrane proteins and methods for the preparation and use thereof
TW201622746A (zh)	2014-04-24	2016-07-01	諾華公司	改善或加速髖部骨折術後身體復原之方法
MX2017010011A (es) *	2015-02-04	2017-11-22	Puretein Bioscience Llc	Metodos para aumentar las caracteristicas de rendimiento en crias.
KR101669140B1 (ko)	2015-04-28	2016-10-26	(주)케어젠	항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도
US10040840B2 (en)	2015-10-02	2018-08-07	Silver Creek Pharmaceuticals, Inc.	Bi-specific annexin A5/IGF-1 proteins and methods of use thereof to promote regeneration and survival of tissue
US11534466B2 (en)	2016-03-09	2022-12-27	Aal Scientifics, Inc.	Pancreatic stem cells and uses thereof
CA3054837A1 (en)	2017-03-24	2018-09-27	Novartis Ag	Methods for preventing and treating heart disease
JP6691503B2 (ja) *	2017-04-13	2020-04-28	任天堂株式会社	ゲームプログラム、ゲーム処理制御方法、およびゲーム装置
JOP20190245A1 (ar)	2017-04-20	2019-10-15	Novartis Ag	أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
TW202342509A (zh) *	2022-01-31	2023-11-01	國立大學法人信州大學	以IGF1R為標的之pre-pro前驅體型嵌合抗原受體表現細胞

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4980286A (en) *	1985-07-05	1990-12-25	Whitehead Institute For Biomedical Research	In vivo introduction and expression of foreign genetic material in epithelial cells
EP0235205B1 (en)	1985-08-22	1992-10-28	Gropep Pty. Ltd.	Peptide analogues of mammalian insulin-like growth factor-1
DE3852636T2 (de)	1987-12-24	1995-05-04	Gropep Pty Ltd	Peptid-analoge vom insulinähnlichen wachstums-faktor 1 (igf-1) oder faktor 2 (igf-2).
GB8819826D0 (en) *	1988-08-20	1988-09-21	Kabivitrum Ab	Glycosylated igf-1
JPH07508025A (ja) *	1992-05-08	1995-09-07	トーマス・ジェファーソン・ユニバーシティ	インスリン様増殖因子（ｉｇｆ−１）類似体
WO1995013290A1 (en)	1993-11-12	1995-05-18	North Shore University Hospital Research Corporation	Method of treating muscular dystrophy
AU2601895A (en)	1994-05-24	1995-12-18	Amgen Boulder Inc.	Modified insulin-like growth factors
GB9605124D0 (en) *	1996-03-11	1996-05-08	Royal Free Hosp School Med	Method of treating muscular disorders
US7118752B2 (en) *	1998-07-22	2006-10-10	University Of Connecticut	Compositions and methods for inhibiting the proliferation and invasiveness of malignant cells comprising E-domain peptides of IGF-I
PT1141014E (pt) *	1999-01-06	2005-04-29	Genentech Inc	Variante mutante do factor de crescimento semelhante a insulina (igf-i)
GB9926968D0 (en) *	1999-11-15	2000-01-12	Univ London	Treatment of neurological disorders
GB0011278D0 (en)	2000-05-10	2000-06-28	Univ London	Repair of nerve damage
WO2002086075A2 (en) *	2001-04-19	2002-10-31	The Scripps Research Institute	Methods and composition for the production of orthoganal trna-aminoacyltrna synthetase pairs
SE0104140D0 (sv) *	2001-12-07	2001-12-07	Astrazeneca Ab	Novel Compounds
GB0202906D0 (en)	2002-02-07	2002-03-27	Univ London	Prevention of myocardial damage
WO2004039956A2 (en)	2002-10-29	2004-05-13	Genentech, Inc.	Compositions and methods for the treatment of immune related diseases
US7355018B2 (en) *	2003-09-30	2008-04-08	Regeneron Pharmaceuticals, Inc.	Modified IGF1 polypeptides with increased stability and potency
GB0426154D0 (en) *	2004-11-29	2004-12-29	European Molecular Biology Lab Embl	IGF-1 novel peptides
EP1674113A1 (en) *	2004-12-22	2006-06-28	F. Hoffmann-La Roche Ag	Conjugates of insulin-like growth factor-1 (IGF-1) and poly(ethylene glycol)
PL1833847T3 (pl) *	2005-01-07	2011-12-30	Regeneron Pharma	Polipeptydy fuzyjne IGF-1 oraz ich zastosowanie terapeutyczne
AU2006224334A1 (en)	2005-03-18	2006-09-21	The Board Of Trustees Of The University Of Illinois	Mecano growth factor peptides and their use
JP2008533114A (ja) *	2005-03-18	2008-08-21	ユーシーエルビジネスパブリックリミテッドカンパニー	メカノ成長因子ペプチドおよびその使用
WO2006106689A1 (ja)	2005-03-31	2006-10-12	Pioneer Corporation	アップグレードモジュール、アプリケーションプログラム、サーバ、及びアップグレードモジュールの配信システム
UA97953C2 (uk)	2006-06-09	2012-04-10	Новартіс Аг	Стабілізовані поліпептиди інсуліноподібного фактора росту

2007
- 2007-06-06 UA UAA200814196A patent/UA97953C2/uk unknown
- 2007-06-06 TW TW096120340A patent/TWI427084B/zh not_active IP Right Cessation
- 2007-06-06 DK DK07798148.8T patent/DK2032155T3/en active
- 2007-06-06 BR BRPI0712147-4A patent/BRPI0712147A2/pt not_active IP Right Cessation
- 2007-06-06 PT PT77981488T patent/PT2032155E/pt unknown
- 2007-06-06 EP EP07798148.8A patent/EP2032155B1/en active Active
- 2007-06-06 AU AU2007257936A patent/AU2007257936B2/en not_active Ceased
- 2007-06-06 WO PCT/EP2007/055608 patent/WO2007141309A2/en active Application Filing
- 2007-06-06 RU RU2008151511/10A patent/RU2477287C2/ru not_active IP Right Cessation
- 2007-06-06 KR KR1020087029888A patent/KR101459789B1/ko not_active Expired - Fee Related
- 2007-06-06 JP JP2009513697A patent/JP2009539805A/ja active Pending
- 2007-06-06 CA CA002653781A patent/CA2653781A1/en not_active Abandoned
- 2007-06-06 AU AU2007255419A patent/AU2007255419A1/en not_active Abandoned
- 2007-06-06 US US12/304,068 patent/US8343918B2/en not_active Expired - Fee Related
- 2007-06-06 CL CL200701614A patent/CL2007001614A1/es unknown
- 2007-06-06 PE PE2007000699A patent/PE20080715A1/es not_active Application Discontinuation
- 2007-06-06 JP JP2009514507A patent/JP5290966B2/ja not_active Expired - Fee Related
- 2007-06-06 MX MX2008015726A patent/MX2008015726A/es active IP Right Grant
- 2007-06-06 CA CA2654944A patent/CA2654944C/en not_active Expired - Fee Related
- 2007-06-06 JO JO2007215A patent/JO2968B1/en active
- 2007-06-06 MX MX2008015657A patent/MX2008015657A/es not_active Application Discontinuation
- 2007-06-06 PL PL07798148T patent/PL2032155T3/pl unknown
- 2007-06-06 EP EP07729975A patent/EP2032154A2/en not_active Withdrawn
- 2007-06-06 WO PCT/US2007/070468 patent/WO2007146689A2/en active Application Filing
- 2007-06-06 AR ARP070102431A patent/AR061242A1/es unknown
- 2007-06-06 ES ES07798148.8T patent/ES2529261T3/es active Active
- 2007-06-06 MY MYPI20084827A patent/MY147856A/en unknown
- 2007-06-06 NZ NZ572708A patent/NZ572708A/en not_active IP Right Cessation
- 2007-06-06 NZ NZ572548A patent/NZ572548A/en not_active IP Right Cessation
- 2007-06-06 HR HRP20150326TT patent/HRP20150326T1/hr unknown
- 2007-06-06 US US12/303,623 patent/US20100173839A1/en not_active Abandoned
- 2007-06-06 SI SI200731622T patent/SI2032155T1/sl unknown
- 2007-06-06 BR BRPI0712052-4A patent/BRPI0712052A2/pt not_active Application Discontinuation
2008
- 2008-11-06 IL IL195156A patent/IL195156A/en not_active IP Right Cessation
- 2008-11-10 CR CR10432A patent/CR10432A/es unknown
- 2008-12-04 GT GT200800273A patent/GT200800273A/es unknown
- 2008-12-05 TN TNP2008000509A patent/TNSN08509A1/en unknown
- 2008-12-08 MA MA31459A patent/MA30503B1/fr unknown
- 2008-12-09 EC EC2008008949A patent/ECSP088949A/es unknown
- 2008-12-11 NO NO20085183A patent/NO20085183L/no not_active Application Discontinuation
- 2008-12-11 NO NO20085184A patent/NO20085184L/no not_active Application Discontinuation
2009
- 2009-01-06 DK DK200900016A patent/DK200900016A/da not_active Application Discontinuation
2012
- 2012-10-30 US US13/664,055 patent/US8722621B2/en not_active Expired - Fee Related
2014
- 2014-01-15 US US14/155,974 patent/US20170066808A9/en not_active Abandoned
2015
- 2015-03-13 CY CY20151100260T patent/CY1116117T1/el unknown
2016
- 2016-03-07 CR CR20160115A patent/CR20160115A/es unknown

Also Published As

Publication number	Publication date
NZ572708A (en)	2011-11-25
CR20160115A (es)	2016-06-14
WO2007141309A2 (en)	2007-12-13
CA2654944A1 (en)	2007-12-21
HRP20150326T1 (hr)	2015-04-24
MA30503B1 (fr)	2009-06-01
PE20080715A1 (es)	2008-07-25
US20170066808A9 (en)	2017-03-09
TW200835698A (en)	2008-09-01
DK200900016A (da)	2009-01-06
CY1116117T1 (el)	2017-02-08
BRPI0712052A2 (pt)	2012-01-10
JP2009539805A (ja)	2009-11-19
MY147856A (en)	2013-01-31
AR061242A1 (es)	2008-08-13
NO20085183L (no)	2009-03-09
CR10432A (es)	2009-01-15
WO2007146689A9 (en)	2010-12-16
DK2032155T3 (en)	2015-03-02
WO2007146689A3 (en)	2008-04-10
MX2008015657A (es)	2009-02-04
WO2007146689A2 (en)	2007-12-21
IL195156A0 (en)	2011-08-01
CA2654944C (en)	2017-01-03
KR20090027197A (ko)	2009-03-16
NO20085184L (no)	2009-03-03
US20140235538A1 (en)	2014-08-21
US8722621B2 (en)	2014-05-13
CA2653781A1 (en)	2007-12-13
JO2968B1 (en)	2016-03-15
HK1126429A1 (en)	2009-09-04
AU2007257936B2 (en)	2011-05-26
PL2032155T3 (pl)	2015-05-29
TNSN08509A1 (en)	2010-04-14
RU2477287C2 (ru)	2013-03-10
AU2007257936A1 (en)	2007-12-21
US8343918B2 (en)	2013-01-01
ES2529261T3 (es)	2015-02-18
EP2032155A2 (en)	2009-03-11
KR101459789B1 (ko)	2014-11-07
UA97953C2 (uk)	2012-04-10
MX2008015726A (es)	2008-12-19
JP2009539383A (ja)	2009-11-19
WO2007141309A3 (en)	2008-05-29
JP5290966B2 (ja)	2013-09-18
IL195156A (en)	2014-07-31
US20130059779A1 (en)	2013-03-07
US20100173839A1 (en)	2010-07-08
GT200800273A (es)	2009-09-16
SI2032155T1 (sl)	2015-04-30
ECSP088949A (es)	2009-01-30
EP2032154A2 (en)	2009-03-11
PT2032155E (pt)	2015-04-07
NZ572548A (en)	2011-06-30
RU2008151511A (ru)	2010-07-20
EP2032155B1 (en)	2014-12-24
AU2007255419A1 (en)	2007-12-13
TWI427084B (zh)	2014-02-21
BRPI0712147A2 (pt)	2012-02-22
US20100234290A1 (en)	2010-09-16

Publication	Publication Date	Title
CL2007001614A1 (es)	2008-08-08	Polipeptido que comprende una proteina del precursor del factor de crecimiento tipo insulina, igf-1 humana, en la cual la escision del peptido e mediante una proteasa se reduce a traves de la modificacion de la proteina del precursor; y su uso para t
ES2486675T3 (es)	2014-08-19	Análogo de péptido de oxintomodulina
CL2013002888A1 (es)	2014-09-05	Anticuerpo que se une peptido antigenico que se obtiene a partir de una proteina tau; composicion farmaceutica que comprende; uso para tratar trastorno o enfermedad neurodegenerativa;kit de ensayo, linea celular (div 2457-2011).
MX2010004298A (es)	2010-05-03	Compuestos que exhiben actividad antagonista de glucagon y agonista de glp-1.
NO20043992L (no)	2004-09-23	Humaniserte antistoffer som gjenkjenner beta amyloid peptid
CL2007003726A1 (es)	2008-05-16	Anticuerpos anti-receptor del factor del crecimiento similar a la insulina i (igf-ir); composicion farmaceutica que lo contiene; y su uso para tratar el cancer.
CL2012003187A1 (es)	2013-07-12	Proteinas de union a il-1 beta humana y ala il-1 alfa humana; conjugado de dicha proteina de unión; composicion para la liberacion de una proteina de unión; composicion farmaceutica.
DE602007003703D1 (de)	2010-01-21	Gegen amyloid-beta peptid gerichtete antikörper
WO2009018126A3 (en)	2009-03-19	Collagen-related peptides and uses thereof
DE602006020407D1 (de)	2011-04-14	Peptide mit neuropeptide-2 rezeptor agonist aktivität
CL2008003660A1 (es)	2010-01-04	Metodo para obtener un peptido insulinotropico tipo glp-1 mediante la union de fragmentos del mismo ya sea en solucion o en fase solida; y peptidos intermediarios aqui empleados.
WO2006097536A3 (en)	2006-12-28	Dimeric peptide agonists of the glp-1 receptor
WO2006097535A3 (en)	2007-04-05	Peptide agonists of the glucagon family with secretin like activity
CO6331291A2 (es)	2011-10-20	Peptidos de señalizacion de la crkl
ATE482281T1 (de)	2010-10-15	Plastiden transit peptide
DK2035447T3 (da)	2017-11-06	Polypeptid
SMAP200800060A (it)	2008-11-12	Anticorpi che legano la proteina umana tirosina fosfatasi beta (hptpbeta) e loro usi
EP2093287A4 (en)	2010-04-21	PEPTIDE BINDER IGG
WO2008002661A3 (en)	2008-11-20	Fusion protein constructs
EP2150811A4 (en)	2010-12-29	TEST FOR HUMAN NATRIURETIC TYPE B PEPTIDE WITH REDUCED CROSS-REACTIVITY WITH OTHER PEPTIDE FORMS
EP2192179A4 (en)	2010-12-01	CDH3 PEPTIDE AND MEDICINAL AGENT COMPRISING SAME
CL2007002931A1 (es)	2008-03-24	Agente tensioactivo que comprende un vehiculo lipidico y una combinacion de analogo polipeptidico de la proteina tensioactiva nativa sp-c y sp-b; composicion tensioactiva y composicion farmaceutica que comprenden dicho agente; uso del agente para tra
ECSP099828A (es)	2010-01-29	Uso de ranolazina para peptido natriuretico tipo-cerebral elevado
CL2012001657A1 (es)	2012-12-21	Polipeptidos de somatotropina porcina porque comprende un aminoacido no codificado de manera natural; uso de dicho polipeptido porque sirve para prevenir infeccion en animal.
ES2616017T3 (es)	2017-06-09	Composiciones que contienen sulfato de condroitina, nattocinasa y compuestos de sulfhidrilo para su uso en el tratamiento de inflamación